Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.54 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.50 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16359952 | 0.90 | POLB (0.64) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL1962182 | 0.90 | POLB (0.64) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL7772982 | 0.89 | POLB (0.63) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL5666385 | 0.88 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3424606 | 0.88 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL3200090 | 0.88 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL15617962 | 0.88 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL1939479 | 0.88 | POLB (0.68) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL8660989 | 0.87 | POLB (0.59) | POLBP2RY2P2RY4P2RY6LMNA | |
| SCHEMBL25456568 | 0.87 | POLB (0.67) | POLBP2RY2P2RY4P2RY6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| EP-4591940-A2 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2025-07-30 | — | — | EP | disclosed |
| EP-4233879-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2025-07-23 | — | — | EP | disclosed |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2024-07-04 | — | — | US | disclosed |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | HEMISPHERIAN AS (NO) | 2024-04-23 | — | — | US | disclosed |
| EP-4233879-A1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2023-08-30 | — | — | EP | disclosed |
| EP-3917538-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2023-07-12 | — | — | EP | disclosed |
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| EP-3917538-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157335-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2020-08-06 | — | — | WO | disclosed |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | INNATE PHARMA (FR) | 2008-12-04 | — | — | US | disclosed |
| EP-1933848-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | Innate Pharma (FR) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039635-A2 | PHOSPHOANTIGEN SALTS OF ORGANIC BASES AND METHODS FOR THEIR CRYSTALLIZATION | INNATE PHARMA (FR) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | POLB 272/4885P2RY2 525/4885P2RY4 481/4885 |
| US-20080300222-A1 | Phosphoantigen Salts Of Organic Bases And Methods For Their Crystallization | HLA-B, LCK, HLA-A | POLB 118/4885P2RY2 1413/4885P2RY4 866/4885 |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | UMPS, UPP1, TYMP | POLB 272/4885P2RY2 525/4885P2RY4 481/4885 |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | POLB 261/4885P2RY2 552/4885P2RY4 518/4885 |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | CDA, DCTD, RNMT | POLB 57/4885P2RY2 203/4885P2RY4 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.